Wolverine Trading, LLC Cti Biopharma Corp Put Options Transaction History

Wolverine Trading, LLC

12 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2023 May 15, 2023	BUY	$4.2 - $6.01 $52,500 - $75,125	12,500 New	12,500 $54,000
Q3 2022 Nov 14, 2022	BUY	$5.36 - $7.43 $63,248 - $87,674	11,800 New	11,800 $66,000
Q2 2022 Aug 15, 2022	SELL	$3.55 - $6.27 $189,925 - $335,445	-53,500 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.9 - $5.23 $79,800 - $219,660	42,000 Added 365.22%	53,500 $268,000
Q4 2021 Feb 14, 2022	SELL	$1.44 - $2.86 $15,264 - $30,316	-10,600 Reduced 47.96%	11,500 $29,000
Q3 2021 Nov 12, 2021	BUY	$2.25 - $3.18 $4,500 - $6,360	2,000 Added 9.95%	22,100 $65,000
Q2 2021 Aug 06, 2021	SELL	$2.16 - $2.62 $1,296 - $1,572	-600 Reduced 2.9%	20,100 $50,000
Q1 2021 May 14, 2021	BUY	$2.68 - $3.8 $55,476 - $78,660	20,700 New	20,700 $55,000
Q3 2019 Nov 14, 2019	SELL	$0.64 - $0.92 $8,704 - $12,512	-13,600 Closed	0 $0
Q2 2019 Aug 20, 2019	BUY	$0.8 - $1.03 $880 - $1,133	1,100 Added 8.8%	13,600 $12,000
Q1 2019 May 15, 2019	SELL	$0.9 - $1.37 $2,520 - $3,836	-2,800 Reduced 18.3%	12,500 $12,000
Q1 2018 May 15, 2018	BUY	$2.7 - $4.06 $41,310 - $62,117	15,300 New	15,300 $60,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.